Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Organogenesis (ORGO : NSDQ)

• Company Description    Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. Number of Employees: 869

• Price / Volume Information    Yesterday's Closing Price: $4.40 Daily Weekly Monthly 20 Day Moving Average: 846,984 shares Shares Outstanding: 126.85 (millions) Market Capitalization: $558.16 (millions) Beta: 1.70 52 Week High: $6.71 52 Week Low: $2.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 38.80% 33.60% 12 Week 4.27% -12.30% Year To Date 37.50% 28.77%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 85 Dan Road - Canton,MA 02021 USA ph: 781-575-0775 fax: - organoir@westwicke.com http://www.organogenesis.com

• General Corporate Information    Officers Gary S. Gillheeney, Sr. - Chairman; Chief Executive Officer and President David Francisco - Chief Financial Officer Alan A. Ades - Director Robert Ades - Director Michael J. Driscoll - Director Peer Information Organogenesis (GSAC) Organogenesis (CASI) Organogenesis (ALCD.) Organogenesis (OMNN) Organogenesis (CGPI.) Organogenesis (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 68621F102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 126.85 Most Recent Split Date: (:1) Beta: 1.70 Market Capitalization: $558.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.30 Price/Cash Flow: 21.09 Price / Sales: 1.22 EPS Growth vs. Year Ago Period: -550.00% vs. Previous Quarter: -425.00% Sales Growth vs. Year Ago Period: -21.17% vs. Previous Quarter: -31.55% ROE 06/30/25 - - 03/31/25 - -4.00 12/31/24 - 0.32 ROA 06/30/25 - - 03/31/25 - -2.26 12/31/24 - 0.19 Current Ratio 06/30/25 - - 03/31/25 - 4.12 12/31/24 - 3.69 Quick Ratio 06/30/25 - - 03/31/25 - 3.67 12/31/24 - 3.35 Operating Margin 06/30/25 - - 03/31/25 - -2.28 12/31/24 - 0.18 Net Margin 06/30/25 - - 03/31/25 - -3.46 12/31/24 - 0.18 Pre-Tax Margin 06/30/25 - - 03/31/25 - -5.29 12/31/24 - -0.58 Book Value 06/30/25 - - 03/31/25 - 1.91 12/31/24 - 2.09 Inventory Turnover 06/30/25 - - 03/31/25 - 4.05 12/31/24 - 4.29 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.17 12/31/24 - 0.27

Powered by Zacks Investment Research ©